Genomic and Proteomic Network for Premature Birth Reseach

描述（由申请人提供）：该提案构成了犹他大学对NICHD早产儿研究基因组和蛋白质组学网络的申请。犹他大学有许多独特的优势，使其成为网络的理想中心。这些包括：1 .多中心合作研究的研究生产力：犹他大学母胎医学（MFM）部门在过去五年中为超过15个多中心临床试验做出了重大贡献，是NICHD/MFMU网络的领先招聘中心。超过12,000名犹他州患者参加了最近完成的FASTER试验，几乎占12个中心试验受试者的32%。犹他大学还参加了死产合作研究网络和全球妇女和儿童健康研究网络。2。早产：犹他大学是国际公认的早产儿临床护理和研究的卓越中心。3。使用基因组和蛋白质组学技术研究早产的专业知识：母胎医学部门发表了使用cDNA微阵列鉴定子宫肌层中分娩特异性表达的基因的文章，并报道了不同种族人群中细胞因子多态性和自发性早产的情况。我们最近也报道了使用蛋白质组学来确定足月和早产的潜在预测因素的经验。生殖和医学遗传学：犹他州独特的人口吸引了许多世界级的遗传学家到大学。将向网络提供最先进的分子和临床遗传能力。五、大学/社区协同作用：犹他州的MFM专家拥有独特的临床和研究伙伴关系，跨越相互竞争的医疗保健系统，为临床研究提供普遍的患者访问。六、成熟的招生策略：研究基础设施目前在四个区域三级护理中心到位，这将继续使犹他大学成为大型多中心试验的领先招募中心之一。

DESCRIPTION (provided by applicant): This proposal constitutes the University of Utah application for the NICHD Genomic and Proteomic Network for Premature Birth Research. The University of Utah has numerous unique strengths that make it an ideal center for the network. These include: I. Research Productivity in Multicenter Collaborative Studies: The University of Utah Maternal-Fetal Medicine (MFM) Division has made substantial contributions to over 15 multicenter clinical trials during the past five years and is a leading recruitment center for the NICHD/MFMU Network. Over 12,000 Utah patients were enrolled in the recently completed FASTER trial, accounting for almost 32% of subjects in the 12- center trial. The University of Utah also participates in the Stillbirth Collaborative Research Network and the Global Network for Women's and Children's Health Research. II. Premature Birth: The University of Utah enjoys international recognition as a center of excellence for clinical care and research on premature birth. III. Expertise in the Use of Genomic and Proteomic Techniques to Study Premature Birth: The Maternal-Fetal Medicine Division has published on the use of cDNA microarray to identify genes with labor-specific expression within myometrium and has also reported on cytokine polymorphisms and spontaneous preterm birth in various ethnic populations. We have also recently reported experience with the use of proteomics to identify potential predictors of term and preterm birth. IV. Reproductive and Medical Genetics: Utah's distinct population has attracted numerous world-class geneticists to the University. State of the art molecular and clinical genetic capabilities will be made available to the Network. V. University / Community Synergy: MFM specialists in Utah have a unique clinical and research partnership that crosses competing health care systems and affords universal access to patients for clinical research. VI. Proven Enrollment Strategy: Research infrastructure is currently in place at four regional tertiary care centers that has and will continue to allow the University of Utah to be among the leading recruitment centers for large multicenter trials.